Is the business good?
How good a business is DNTH?
Dianthus Therapeutics, Inc. earns −60% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−60%
Return on invested capital · cost of capital 9.0% · 69 points below what the capital costs: growth destroys value
- Share count, year on year
- +56%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2021 | −5060% |
| FY2022 | −463% |
| FY2023 | −1705% |
| FY2024 | −1634% |
| FY2025 | −8739% |
Details›
- Free cash flow, trailing twelve months
- −$156M
- Net income, trailing twelve months
- −$192M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −60%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.